-
Featured Authors
-
Archives
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Latest From Biotech Now
The Michael J. Fox Foundation Launches New Funding Opportunities
The Michael J. Fox Foundation (MJFF) is committed to sharing the risk of drug development with researchers from academia and industry alike in order to keep promising research moving forward along the Parkinson’s disease (PD) drug pipeline. To date, MJFF has funded over $300 million in research, $83 million of which has been awarded to more than 180 unique, industry-led projects. On February 20, MJFF launched nine funding programs, three of which are new to Read More >
A Bright Future for Orphan Disease Indications
In celebration of National Rare Disease Day BIO’s Industry Analysis team took a look at recently-approved drugs in the BioMedTracker database with an orphan indication designation. Our research found that 2012 saw the greatest number of approvals of therapies for orphan indications going back all the way to 2000 (This count includes previously approved drugs with new, orphan indication approvals). Overall, 24 therapies were approved in orphan indications last year, including drugs for Anthrax, Gaucher’s Read More >
Navigating the Rare Disease World
The international orphan drug marketplace is expected to grow some 30 percent by 2014, fueled by the entrance of big pharmaceutical companies and U.S. legislation favoring development and coverage. This growth promises to improve the health of patients with debilitating and life-threatening disorders. Hoping to further the rare disease dialogue and relationship building opportunities, the 2013 Orphan Disease Forum will provide unique perspective on the orphan drug marketplace, regulatory considerations and much more. Operating within Read More >
Rare Disease Day: Families and Advocacy Groups Drive Treatments for Rare Diseases
Today, we celebrate Rare Disease Day to recognize the path to treatments and cures is paved by families and caregivers working with advocacy groups, medical advisors, and dedicated researchers. Of the many people touched by and involved in the world of rare diseases, patients and their families are inarguably the most passionate advocates for rare disease research. When their disease-focused family foundations work together, pool their funds, and align their efforts, the results can be Read More > How Countries Can Boost Their Biotech Industry
How can countries and regions boost the biotech industry within their borders? Working with several member companies, BIO developed a Global Policy Platform to serve as a roadmap for policymakers seeking to create an environment for the biotech industry to grow and prosper. These policy principles include four components: (i) research collaboration; (ii) intellectual property rights; (iii) regulatory approval; and (iv) market access. In addition, the Global Policy Platform includes best practices from around the Read More >
